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Objectives This post-hoc analysis of the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial
was designed to assess the comparative treatment efficacy of high-dose atorvastatin and usual-dose simvastatin
for the prevention of events subsequent to the first event, using the Wei, Lin, and Weissfeld method.
Background Time-to-first-event analysis of data is frequently utilized to provide efficacy outcome information in coronary
heart disease prevention trials. However, during the course of such long-term trials, a large number of events
occur subsequent to the first event, the analysis of which will be precluded by this approach.
Methods The Wei, Lin, and Weissfeld method allows the analysis of repeated occurrence of events of the same type or of
entirely different natures. It regards the recurrence times as multivariate event (failure) times, and models the
marginal (individual) distribution for each event with the Cox proportional hazards model.
Results In the IDEAL trial, compared with patients taking simvastatin 20 to 40 mg daily, patients receiving atorvastatin
80 mg daily had their relative risk of a first cardiovascular event reduced by 17% (p  0.0001), of a second by 24%
(p  0.0001), of a third by 19% (p  0.035), of a fourth by 24% (p  0.058), and of a fifth by 28% (p  0.117).
Conclusions Our results indicate that intensive statin therapy continues to be more effective than standard statin therapy,
even beyond the first event, and suggest that clinicians should not hesitate to prescribe high-dose statin therapy
for patients experiencing multiple recurrent cardiovascular events. (J Am Coll Cardiol 2009;54:2353–7)
© 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.08.035a
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Statin Therapy and Recurrent Cardiovascular Events December 15/22, 2009:2353–7CHD death, are usually defined as
primary end points. However, the
classical analysis of time-to-first
hard end points has 2 shortcom-
ings. First, during the course of
long-term trials, a large number of
events occur subsequent to the
first, the analysis of which, despite
their clinical and health economics
importance, will be precluded by
the time-to-first-event approach.
Second, recent developments have
rovided marked improvements in the treatment of cardiovas-
ular (CV) atherosclerotic disease, changing the scope and
elevance of atherosclerosis prevention trials: patients may be
ospitalized for acute coronary syndrome and treated with
oronary angioplasty or thrombolysis before progressing to MI.
hus, the proportion of hard outcome variables has become
maller compared with the number of other first events, such as
evascularization procedures, hospitalizations for unstable an-
ina pectoris or congestive heart failure, and peripheral artery
isease. This “changing face of CV risk” (1) has led to the
ituation where an increasing proportion of outcome variables
re classified as secondary end points. Therefore, to gain
aximal information from clinical trials, it has become impor-
ant to analyze more inclusive end points containing a number
f different types of events in addition to the conventional
rimary outcome variables, and to analyze time to events
ccurring after the first event.
In a post-hoc analysis of a major statin trial, the IDEAL
Incremental Decrease in End Points Through Aggressive
ipid Lowering) trial, we aimed to assess the comparative
reatment efficacy of 2 statin regimens for the events beyond
he first, using the broadest secondary end point (any
ardiovascular disease [CVD]), consisting of the primary
nd point (CHD death, nonfatal MI, and resuscitated
ardiac arrest) plus the following: stroke, revascularization,
ospitalization for unstable angina pectoris, hospitalization
or congestive heart failure, and peripheral artery disease. In
his type of study, participants may experience after the first
vent any of the outcome variables noted in the preceding
ext, and nonfatal events may occur in any order. We
mployed Cox’s proportional hazards model to estimate
reatment hazard ratios separately for the time to first,
econd, third, fourth, and fifth events.
ethods
atient population. The IDEAL study randomly allocated
,888 patients with a history of confirmed acute MI according
o the prospective, randomized, open-label, blinded end point
esign (2); full design details and end point results were
ublished earlier (3,4). In short, patients were men (80.8%)
nd women 80 years of age who qualified for statin
herapy. Exclusion criteria comprised any known contrain-
Abbreviations
and Acronyms
CHD  coronary heart
disease
CV  cardiovascular
CVD  cardiovascular
disease
MI  myocardial infarction
WLW  Wei, Lin, and
Weissfeldication to statin therapy, liver enzymes2 times the upper wimit of normal, and using other lipid-lowering drugs.
andomization was carried out through a central interactive
oice-response system with equal allocation to either ator-
astatin 80 mg or simvastatin 20 mg daily within each
enter. There was no wash-out or run-in period. Simvastatin-
reated patients could be titrated to 40 mg daily if plasma
holesterol at 24 weeks was at least 5.0 mmol/l. Except for
uch cases, lipid levels were not revealed to study personnel
uring the study. High-dose atorvastatin compared with
sual-dose simvastatin reduced the first major coronary
vents (major cardiovascular event: fatal and nonfatal MI or
esuscitated cardiac arrest; primary end point) by 11% (p 
.07), and any CV event (major cardiovascular event plus
troke, hospitalization for unstable angina pectoris, coronary
evascularization procedures, peripheral vascular disease,
nd hospitalization for nonfatal congestive heart failure) by
6% (p  0.001).
tatistical analysis. In 1989, Wei, Lin, and Weissfeld pro-
osed a marginal approach (the WLW method) to the analysis
f multiple event data, based on the Cox proportional hazards
odel (5). This method is used in the analysis of recurrent
vents, namely, the repeated occurrence of the same type of
vent or the occurrence of events of entirely different natures
6). The WLW analysis regards the recurrence times as
ultivariate event (failure) times, and models the marginal
individual) distribution for each event with the Cox propor-
ional hazards model, allowing for dependence among the
vents. In this method, the individual subject is simultaneously
t risk for all events; this preserves the randomization, and
ermits valid treatment effect estimation for recurrences past
he first event (7). This is an advantage of the WLW approach.
or example, if 5 recurrences are being analyzed, a person who
xperiences only 1 recurrence is considered to be at risk not
nly for a second recurrence but also for a third, fourth, and
fth recurrence. In contrast to other methods (8), the WLW
rocedure allows for valid analysis of treatment effects for
ecurrences subsequent to the first event due to the preservation
f randomization (7). The WLW procedure can be applied to
he model also for terminating events such as death or
ropping out of the study (7,9). The WLW method has been
sed for analysis treatment trials of chronic diseases, such as
uman immunodeficiency virus/acquired immunodeficiency
yndrome (10,11), recurrent malignancies in the urinary blad-
er (5,12), and rejection episodes in kidney transplant patients
13), but not, to our knowledge, in trials of CHD prevention.
The great majority of events in the IDEAL trial were
onfatal. We conducted a post-hoc time-to-event analysis
o estimate the treatment hazard ratio separately for the
ime to the first, second, third, fourth, and fifth CV events.
n addition, because treatment effect was tested on multiple
vent times, the WLW method was used to perform an
mnibus test that controlled for type I error, to compare
reatment effect across the 5 events. Times to events past the
rst event were computed from the time of randomization,
nd all subjects were included in the analysis, regardless of
hether they had a first event or not. In addition, for our
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December 15/22, 2009:2353–7 Statin Therapy and Recurrent Cardiovascular Eventsnalysis of any CV event, CV deaths were a component of
he end point. The CV events were censored at the time of
eath for subjects who died of a non-CV cause. So, for
xample, if a subject had a nonfatal MI on day 50 and died
non-CV death on day 55, the subject’s first event will be
ay 50, and the second, third, fourth, and fifth events will be
ensored on day 55. Adjustments were made for age and sex
or the WLW analysis, and SAS version 8.0 software (SAS
nstitute, Cary, North Carolina) was used.
esults
f the 8,888 patients randomized in the IDEAL study
Fig. 1), 2,546 experienced a first any CV event, 1,048
xperienced a second event, 416 a third event, 192 a fourth,
nd 93 a fifth event (Table 1). As shown in Figure 2,
atients randomly assigned to atorvastatin 80 mg/day,
ompared with patients randomly assigned to simvastatin 20
o 40 mg/day, had a reduction in the relative risk of a first
vent by 17% (p  0.0001), of a second event by 24% (p 
.0001), of a third event by 19% (p  0.035), of a fourth
vent by 24% (p  0.058), and of a fifth event by 28% (p 
.117). The omnibus test was also applied for the first
hrough fifth events, showing that patients randomly allo-
ated to atorvastatin compared with patients allocated to
imvastatin had a relative risk reduction of 17% (p  0.001)
cross all 5 events.
The main types of the first 2,546 events were coronary
evascularization (32%), nonfatal MI (18%), and hospital-
zation for unstable angina (14%). The corresponding per-
entages were 42%, 15%, and 9% for the second 1,048
vents; and 32%, 15%, 11% for the 416 third events—
uggesting that no major changes in the event profilet
Figure 1 Flow of Participants Through the IDEAL Trialccurred in the first through third events with sufficient
umbers of events for comparing percentage distribution.
iscussion
sing the WLW method, we compared the efficacy of
ntensive and standard statin treatment in the prevention of
hese repeated occurrences of events and showed that
ntensive therapy increased relative risk reductions signifi-
antly for the second and third events. Risk reductions were
ven greater for the fourth and fifth events but lost signif-
cance, probably due to smaller event numbers. We chose
his approach because treatment effects on these recurrent
HD manifestations are of great interest for both clinicians
nd patients, and they add significantly to disease and health
conomic burden.
This analysis provides new insights into the treatment of
atients experiencing repeated occurrences of CVD. Often
he question arises whether to continue high-dose statin
herapy if such has been prescribed. The treating physician
uspiciously considers the increasing possibility of drug–
rug interactions, and the patient may feel that it might be
rudent to use a smaller statin dose. Our results seem to
ndicate that, especially for such patients, intensive statin
herapy is preferable to standard therapy.
A number of statistical methods have been developed to
nable comparative analyses of treatment effects on multiple
ypes of disease manifestations, which may occur repeatedly
n one form or another, or may result in death (6). The
LW method is particularly useful for chronic diseases that
ay present with several types of first events, and in which
atients may undergo each of several types of event more
han once, the occurrence of 1 type of event not precluding
hat of others (12,13). In this analysis, all subjects (in this
ase 8,888 persons) are at risk from the start of the trial, and
hus randomization is maintained. This differs from ap-
roaches that consider subjects at risk for a fifth event only
fter the recurrence of a fourth event (8). Although such an
pproach appears to make more sense, it does not allow
alid estimation of multiple recurrent events as randomiza-
umber of Any CV and Deaths*Table 1 Number of Any CV and Deaths*
Subjects With
Any CV Event
CV
Deaths
Non-CV
Deaths
Non-CV deaths 223
First any CV event 2,546 221
Non-CV deaths 50
Second any CV event 1,048 109
Non-CV deaths 19
Third any CV event 416 52
Non-CV deaths 2
Fourth any CV event 192 24
Non-CV deaths 2
Fifth any CV event 93 14
Number of patients at risk is 8,888 for all categories.
CV  cardiovascular.ion is lost. The WLW approach considers all patients to be
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Statin Therapy and Recurrent Cardiovascular Events December 15/22, 2009:2353–7t risk for all events, and can be applied to modeling also for
erminating events such as death or being removed from the
tudy for any reason (7,9).
The WLW method has been used for comparative
nalysis of antiretroviral treatments for acquired immuno-
eficiency syndrome (11). This disease may typically present
s a variety of different opportunistic infections or as the
nset of various types of malignancies, and the patients may
xperience recurrences of any of these in no predictable
rder, or the follow-up may be terminated by death related
o acquired immunodeficiency syndrome. In a similar vein,
VDs may present as any kind of CV event that may
epeatedly occur in one form or another, and in no predict-
ble order. We are not aware of WLW analyses of previous
HD prevention trials, but the method has been used for
xamining multiple biopsies per patient for the rejection
nalysis in a trial comparing tacrolimus and cyclosporine
egimens in cardiac transplantation (14).
tudy limitations. The following limitations of our analy-
is must be considered. The analyses were based on original
reatment group assignments so that switchovers in therapy
nd discontinuations were not taken into account. Also, our
nalysis does not provide insight into the interrelationship
mong event times, nor how prior events affect the risk of
ubsequent events. Thus, the WLW method does not take
nto account dependences that are probably present between
ecurrences: the severity of the second event may be influ-
nced by the type of the first event, for example, a severe MI
ay have different consequences than a timely coronary
evascularization.
onclusions
statistical method that, to our knowledge, has not been
reviously used for analysis of CV prevention trials was
Figure 2 Effects of Atorvastatin 80 mg Daily Versus Simvastat
Effects are a composite of the following: fatal or nonfatal myocardial infarction, re
revascularization procedures, peripheral vascular disease, and hospitalization for n
dence interval.mployed for the analysis of the IDEAL study cohort. Wexplored the possibility that new information concerning
reatment efficacy of intensive statin therapy compared with
tandard statin therapy could be gained by analysis of
epeated occurrences (after the first event) of CV events of
ifferent kinds. The method allows analysis of not only time
o first CV event, but also time to second, third, fourth, and
fth events. Our results indicate that intensive statin therapy
ontinued to be more effective than standard statin therapy
ven beyond the first event.
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